CAH Treatment
Brief description of study
To evaluate the safety and tolerability of CRN04894 Change from Baseline in morning (before 11:00 AM) serum A4 (androstenedione) at Week 12. Change from Baseline in morning (before 11:00) serum 17-OHP (17-hydroxyprogesterone) at Week 12.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
